|
Cirrhosis, % (n)
|
6% (23/385)
|
31.6 % (24/76)
|
7.2 (3.7-13.8)
|
<0.0001
|
|
HCV-RNA >500.000 IU/ml, % (n)
|
50.1% (191/381)
|
35.5 % (27/76)
|
0.5 (0.3-0.9)
|
0.02
|
|
PegIFN alfa-2b vs alfa-2a, % (n)
|
15.5% (61/385)
|
30.3 % (23/76)
|
2.34 (1.3-4.1)
|
0.002
|
|
PegIFN reduction, % (n)
|
11.7% (45/385)
|
5.3 % (4/76)
|
0.4 (0.1-1.1)
|
0.09
|
|
Stop PegIFN, % (n)
|
14% (54/385)
|
30.3 % (23/76)
|
2.6 (1.5-4.6)
|
0.0005
|
|
RBV reduction, % (n)
|
14.5% (56/385)
|
14.5 % (11/76)
|
0.9 (0.4-1.9)
|
0.987
|
|
Stop RBV, % (n)
|
9.6% (37/385)
|
27.6 % (21/76)
|
3.5 (1.9-6.5)
|
<0.0001
|
|
Age >45 years, % (n)
|
51.9% (200/385)
|
50% (38/76)
|
0.92 (0.5-1.5)
|
0.76
|
|
Male gender, % (n)
|
63.4% (244/385)
|
82.9 % (63/76)
|
2.8 (1.5-5.4)
|
0.009
|
|
Genotype 3, % (n)
|
47% (181/385)
|
94.7 % (72/76)
|
20.2 (7.8-66.2)
|
<0.0001
|
|
PLT <130,000 cell/mm3, % (n)
|
7.5% (29/385)
|
32.9 % (25/76)
|
6 (3.2-11)
|
<0.0001
|
|
HIV RNA <50 cp/ml, % (n)
| |
90.8% (69/76)
| | |
|
Patients in HAART, % (n)
| |
98.7% (75/76)
| | |
|
Variables
|
HIV- (n = 385)
|
HIV+ (n = 76)
| |
p
-value
|
|
ALT, IU/l, mean (DS)
|
117.6 (111.4)
|
114.6 (74.7)
| |
0.2126
|
|
AST, IU/l, mean (DS)
|
69.2 (66.3)
|
74.8 (49.1)
| |
0.0123
|
|
BMI, mean (DS)
|
25.2 (4.2)
|
23.7 (3.1)
| |
0.006
|
|
Cholesterol, mg/dl, mean (DS)
|
175 (42.7)
|
150.5 (40)
| |
<0.0001
|
|
Triglycerids, mg/dl, mean (DS)
|
88.8 (43.8)
|
112.3 (63)
| |
0.001
|
|
Age, years, mean (DS)
|
46.1 (12.3)
|
44 (5.5)
| |
0.33
|
|
Glycemia, mean (DS)
|
94.4 (19.1)
|
90.8 (12.2)
| |
0.082
|
|
Hb, g/dl, mean (DS)
|
14.9 (1.5)
|
14.5 (2.1)
| |
0.095
|
|
PT, mean (DS)
|
103.6 (11.4)
|
100.5 (13.4)
| |
0.12
|
|
Neutrophils, cell/mm3, mean (DS)
|
3400 (1231)
|
3080 (1342)
| |
0.014
|
|
Weeks of treatment, mean (DS)
|
19 (8)
|
41 (17)
| |
<0.0001
|
|
Bilirubin, mg/dl, mean (DS)
|
0.7 (0.4)
|
1.5 (1.4)
| |
<0.0001
|
|
Albumin, g/dl, mean (DS)
|
4.5 (2.2)
|
4.4 (0.4)
| |
0.896
|
|
CD4+ cell count (cell/mm3), mean (DS)
| |
489 (273)
| | |
|
Nadir CD4 (cell/mm3), mean (DS)
| |
213 (158)
| | |
